BROSSARD, Quebec, May 26, 2022 (GLOBE NEWSWIRE) – Diagnos Inc. (“DIAGNOS,” the “Company” or “we”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection and health issues thanks to FL Artificial Intelligence (AI) technologyThere isRE is pleased to announce the launch of an autonomous artificial intelligence solution testing phase dedicated to diabetic retinopathy screening, in partnership with the Center Hospitalitale de l’University de Montreal (CHUM).
It is with great pleasure that DIAGNOS and CHUM are embarking on clinical studies that will, with precision, establish the level of effectiveness of autonomous algorithms for the identification and classification of diabetic retinopathy patients by disease severity level. .
“This episode concludes a partnership aimed at automated detection of diabetic retinopathy, which began in June 2018.” Mr. Andre Laurente, President of Diagons. This phase of testing and performance analysis was approved by CHUM following a rigorous independent evaluation process performed by CHUM physicians, following the positive results of assessment of classification algorithms by level of intensity in autonomous mode in recent months.
“This project is fully in line with CHUM’s desire to improve patient service access through partnerships that allow the development and integration of innovative solutions. Directed Dr. Fabrice Brunett, President and CEO of CHUM.
Retinal fundus images of more than 600 diabetics in CHUM’s Endocrinology Department will be analyzed by Diagons’ Neoretina Artificial Intelligence Deep Learning Algorithm in collaboration with CHUM’s Ophthalmology Department. This solution allows for the identification of lesions caused by diabetic retinopathy and the classification of disease evolution by level of severity. Conducted in a “double-blind” type of comparison mode, this test will allow CHUM professionals to precisely determine the level of operation and accuracy of the Neuretina Autonomous Algorithm.
Regarding the advantages of this automated screening technology, Head of the Department of Endocrinology at CHUM. Andre Boucher, Delighted with the increased amount of screening that will be accomplished: “Diabetic retinopathy affects a large number of diabetic patients. However, since in the early stages of the disease, patients are usually asymptomatic and the symptoms do not usually appear until a more advanced stage of the disease, this method of independent screening is easily carried out during the annual examination of patients, will help reduce the number of complications. A
As Dr. Selim Lahaud, Head of Chom Eye DepartmentThe latter agrees with his colleague and confirms that the use of artificial intelligence solutions created by screening diagnostics for diabetic retinopathy will contribute to the priority and improvement of patient care by ophthalmologists.
In addition to being accurate, efficient and fast, DIAGNOS’s artificial intelligence screening solutions allow a significant reduction in costs and allow early detection of pathologies. Since diabetes is the second leading cause of blindness in Canada, integrating these solutions into medical follow-up programs, such as those given to diabetic patients, allows a large number of patients to save their eyesight!
About the University of Montreal Hospital Center (CHUM)
The University of Montreal Hospital Center is an innovative hospital serving patients. It provides the best care, specialized and superspecialized for patients and the entire Quebec population. Thanks to its unique skills and innovation, it improves the health of the adult and elderly population. As a hospital center for the University of Montreal, CHUM has methods of care, research, teaching, health promotion as well as technology evaluation and health intervention to continually improve the quality of care and health. Of the people. Since the fall of 2017, patients and their loved ones have been enjoying new hospital experiences at the new CHUM facilities.
More information is available on the website www.chumontreal.qc.ca
DIAGNOS is a publicly traded Canadian company that aims to initially detect serious health problems using its artificial intelligence (AI) platform FLAIRE. Makes applications like FLAIRE CARA (Computer Assisted Retina Analysis) faster change and development. CARA’s image enhancement algorithms make sharp, clear and retinal images easier to analyze. CARA is a low cost tool used for real-time screening of many patients. CARA sales clearance has been granted by the following regulatory bodies; Health Canada, FDA (United States), CE (Europe), Coffepris (Mexico), and Saudi FDA (Saudi Arabia).
More information is available on the websites www.diagnos.com And www.sedar.com.
Neither the TSX Venture Exchange nor its regulation service provider (as the term is defined in the TSX Venture Exchange Policy) assumes responsibility for the adequacy or accuracy of this release.
This press release may contain front-end information. We cannot guarantee that the foresight information provided will be accurate, as there may be a material difference between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or correct new information, future events or any other far-sighted information as a result. The advance information contained in this press release is clearly qualified by this cautionary statement.
CONTACT: Pour plus d’informations sur ce communiqué, veuillez communiquer avec : M. André Larente, président Diagnos Inc. Tél. : +1 450-678-8882, poste 224 Courriel : firstname.lastname@example.org Andrée-Anne Toussaint Centre hospitalier de l’Université de Montréal (CHUM) Tél. : 514 890-8000, poste 23675 Courriel : email@example.com
Source: https: //www.globenewswire.com/news-release/2022/05 …